Ipilimumab in patients with melanoma and autoimmune disease View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2014-10-14

AUTHORS

Chrisann Kyi, Richard D Carvajal, Jedd D Wolchok, Michael A Postow

ABSTRACT

Cytotoxic T-Lymphocyte Antigen 4 (CTLA-4), an immune-checkpoint receptor and regulator of T-cell activation, has become an important therapeutic target for immunotherapy in cancer and autoimmune diseases. To date, clinical trials involving cancer immunotherapies, such checkpoint blocking antibodies directed at CTLA-4 (ipilimumab), have excluded patients with underlying autoimmune disease given concern for potential triggering of autoimmune exacerbations. We present the first known cases to our knowledge of two patients with active autoimmune diseases who received ipilimumab. In this limited clinical experience, no serious exacerbations of underlying autoimmunity have yet been observed, and one patient benefited from ipilimumab. These cases advocate for further investigation of the safety of cancer immunotherapies in cancer patients with underlying autoimmune conditions in carefully designed clinical trials with cautious monitoring. More... »

PAGES

35

Identifiers

URI

http://scigraph.springernature.com/pub.10.1186/s40425-014-0035-z

DOI

http://dx.doi.org/10.1186/s40425-014-0035-z

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1011546195

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/25349698


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1107", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Immunology", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "New York-Presbyterian Hospital - Weill Cornell Medical College, 525 E 68th Street, 10065, New York, NY, USA", 
          "id": "http://www.grid.ac/institutes/grid.5386.8", 
          "name": [
            "New York-Presbyterian Hospital - Weill Cornell Medical College, 525 E 68th Street, 10065, New York, NY, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Kyi", 
        "givenName": "Chrisann", 
        "id": "sg:person.01070606664.05", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01070606664.05"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Weill Cornell Medical College, 525 E 68th Street, 10065, New York, NY, USA", 
          "id": "http://www.grid.ac/institutes/grid.5386.8", 
          "name": [
            "Melanoma and Immunotherapeutics Oncology Service, Memorial Sloan Kettering Cancer Center, 300 East 66th Street, 10065, New York, NY, USA", 
            "Weill Cornell Medical College, 525 E 68th Street, 10065, New York, NY, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Carvajal", 
        "givenName": "Richard D", 
        "id": "sg:person.0726366600.25", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0726366600.25"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Weill Cornell Medical College, 525 E 68th Street, 10065, New York, NY, USA", 
          "id": "http://www.grid.ac/institutes/grid.5386.8", 
          "name": [
            "Melanoma and Immunotherapeutics Oncology Service, Memorial Sloan Kettering Cancer Center, 300 East 66th Street, 10065, New York, NY, USA", 
            "Weill Cornell Medical College, 525 E 68th Street, 10065, New York, NY, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Wolchok", 
        "givenName": "Jedd D", 
        "id": "sg:person.0645565266.33", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0645565266.33"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Weill Cornell Medical College, 525 E 68th Street, 10065, New York, NY, USA", 
          "id": "http://www.grid.ac/institutes/grid.5386.8", 
          "name": [
            "Melanoma and Immunotherapeutics Oncology Service, Memorial Sloan Kettering Cancer Center, 300 East 66th Street, 10065, New York, NY, USA", 
            "Weill Cornell Medical College, 525 E 68th Street, 10065, New York, NY, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Postow", 
        "givenName": "Michael A", 
        "id": "sg:person.0663446543.06", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0663446543.06"
        ], 
        "type": "Person"
      }
    ], 
    "datePublished": "2014-10-14", 
    "datePublishedReg": "2014-10-14", 
    "description": "Cytotoxic T-Lymphocyte Antigen 4 (CTLA-4), an immune-checkpoint receptor and regulator of T-cell activation, has become an important therapeutic target for immunotherapy in cancer and autoimmune diseases. To date, clinical trials involving cancer immunotherapies, such checkpoint blocking antibodies directed at CTLA-4 (ipilimumab), have excluded patients with underlying autoimmune disease given concern for potential triggering of autoimmune exacerbations. We present the first known cases to our knowledge of two patients with active autoimmune diseases who received ipilimumab. In this limited clinical experience, no serious exacerbations of underlying autoimmunity have yet been observed, and one patient benefited from ipilimumab. These cases advocate for further investigation of the safety of cancer immunotherapies in cancer patients with underlying autoimmune conditions in carefully designed clinical trials with cautious monitoring.", 
    "genre": "article", 
    "id": "sg:pub.10.1186/s40425-014-0035-z", 
    "isAccessibleForFree": true, 
    "isFundedItemOf": [
      {
        "id": "sg:grant.2438793", 
        "type": "MonetaryGrant"
      }, 
      {
        "id": "sg:grant.2622404", 
        "type": "MonetaryGrant"
      }, 
      {
        "id": "sg:grant.2682501", 
        "type": "MonetaryGrant"
      }
    ], 
    "isPartOf": [
      {
        "id": "sg:journal.1049249", 
        "issn": [
          "2051-1426"
        ], 
        "name": "Journal for ImmunoTherapy of Cancer", 
        "publisher": "BMJ", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "2"
      }
    ], 
    "keywords": [
      "autoimmune diseases", 
      "cancer immunotherapy", 
      "clinical trials", 
      "cytotoxic T-lymphocyte antigen-4", 
      "T-lymphocyte antigen-4", 
      "active autoimmune disease", 
      "underlying autoimmune disease", 
      "immune checkpoint receptors", 
      "limited clinical experience", 
      "T cell activation", 
      "important therapeutic target", 
      "autoimmune exacerbation", 
      "serious exacerbations", 
      "autoimmune conditions", 
      "antigen-4", 
      "CTLA-4", 
      "cancer patients", 
      "cautious monitoring", 
      "therapeutic target", 
      "clinical experience", 
      "patients", 
      "ipilimumab", 
      "immunotherapy", 
      "disease", 
      "exacerbation", 
      "further investigation", 
      "trials", 
      "autoimmunity", 
      "melanoma", 
      "cancer", 
      "antibodies", 
      "receptors", 
      "cases", 
      "activation", 
      "potential triggering", 
      "such checkpoints", 
      "safety", 
      "target", 
      "regulator", 
      "checkpoint", 
      "date", 
      "triggering", 
      "experience", 
      "monitoring", 
      "concern", 
      "knowledge", 
      "investigation", 
      "conditions"
    ], 
    "name": "Ipilimumab in patients with melanoma and autoimmune disease", 
    "pagination": "35", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1011546195"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1186/s40425-014-0035-z"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "25349698"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1186/s40425-014-0035-z", 
      "https://app.dimensions.ai/details/publication/pub.1011546195"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-08-04T17:03", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20220804/entities/gbq_results/article/article_641.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1186/s40425-014-0035-z"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1186/s40425-014-0035-z'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1186/s40425-014-0035-z'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1186/s40425-014-0035-z'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1186/s40425-014-0035-z'


 

This table displays all metadata directly associated to this object as RDF triples.

138 TRIPLES      20 PREDICATES      73 URIs      65 LITERALS      7 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1186/s40425-014-0035-z schema:about anzsrc-for:11
2 anzsrc-for:1107
3 schema:author N62b3f09aeef443258e41641cef92d2bf
4 schema:datePublished 2014-10-14
5 schema:datePublishedReg 2014-10-14
6 schema:description Cytotoxic T-Lymphocyte Antigen 4 (CTLA-4), an immune-checkpoint receptor and regulator of T-cell activation, has become an important therapeutic target for immunotherapy in cancer and autoimmune diseases. To date, clinical trials involving cancer immunotherapies, such checkpoint blocking antibodies directed at CTLA-4 (ipilimumab), have excluded patients with underlying autoimmune disease given concern for potential triggering of autoimmune exacerbations. We present the first known cases to our knowledge of two patients with active autoimmune diseases who received ipilimumab. In this limited clinical experience, no serious exacerbations of underlying autoimmunity have yet been observed, and one patient benefited from ipilimumab. These cases advocate for further investigation of the safety of cancer immunotherapies in cancer patients with underlying autoimmune conditions in carefully designed clinical trials with cautious monitoring.
7 schema:genre article
8 schema:isAccessibleForFree true
9 schema:isPartOf N56a406cbbfb14e638d31bac9063e157d
10 N5710c67e4d0f496aa60cad03c6d74200
11 sg:journal.1049249
12 schema:keywords CTLA-4
13 T cell activation
14 T-lymphocyte antigen-4
15 activation
16 active autoimmune disease
17 antibodies
18 antigen-4
19 autoimmune conditions
20 autoimmune diseases
21 autoimmune exacerbation
22 autoimmunity
23 cancer
24 cancer immunotherapy
25 cancer patients
26 cases
27 cautious monitoring
28 checkpoint
29 clinical experience
30 clinical trials
31 concern
32 conditions
33 cytotoxic T-lymphocyte antigen-4
34 date
35 disease
36 exacerbation
37 experience
38 further investigation
39 immune checkpoint receptors
40 immunotherapy
41 important therapeutic target
42 investigation
43 ipilimumab
44 knowledge
45 limited clinical experience
46 melanoma
47 monitoring
48 patients
49 potential triggering
50 receptors
51 regulator
52 safety
53 serious exacerbations
54 such checkpoints
55 target
56 therapeutic target
57 trials
58 triggering
59 underlying autoimmune disease
60 schema:name Ipilimumab in patients with melanoma and autoimmune disease
61 schema:pagination 35
62 schema:productId N5495fbea437c42909252a2aa89ef0a77
63 N7079919111794cb185fa929b96257bfa
64 Nc0268ac262a4400f89ea6ea45d993e1f
65 schema:sameAs https://app.dimensions.ai/details/publication/pub.1011546195
66 https://doi.org/10.1186/s40425-014-0035-z
67 schema:sdDatePublished 2022-08-04T17:03
68 schema:sdLicense https://scigraph.springernature.com/explorer/license/
69 schema:sdPublisher N0810ed4aefbf4f88ae49b9ada0538554
70 schema:url https://doi.org/10.1186/s40425-014-0035-z
71 sgo:license sg:explorer/license/
72 sgo:sdDataset articles
73 rdf:type schema:ScholarlyArticle
74 N0810ed4aefbf4f88ae49b9ada0538554 schema:name Springer Nature - SN SciGraph project
75 rdf:type schema:Organization
76 N5495fbea437c42909252a2aa89ef0a77 schema:name dimensions_id
77 schema:value pub.1011546195
78 rdf:type schema:PropertyValue
79 N56a406cbbfb14e638d31bac9063e157d schema:volumeNumber 2
80 rdf:type schema:PublicationVolume
81 N5710c67e4d0f496aa60cad03c6d74200 schema:issueNumber 1
82 rdf:type schema:PublicationIssue
83 N62b3f09aeef443258e41641cef92d2bf rdf:first sg:person.01070606664.05
84 rdf:rest N8bd70764923c4fb7aa03b42ddc45ac79
85 N7079919111794cb185fa929b96257bfa schema:name pubmed_id
86 schema:value 25349698
87 rdf:type schema:PropertyValue
88 N85f30690a40e4a67866f8a873957291f rdf:first sg:person.0663446543.06
89 rdf:rest rdf:nil
90 N8bd70764923c4fb7aa03b42ddc45ac79 rdf:first sg:person.0726366600.25
91 rdf:rest Nc7724a0b1fae4961bb87ece2f51e4f6b
92 Nc0268ac262a4400f89ea6ea45d993e1f schema:name doi
93 schema:value 10.1186/s40425-014-0035-z
94 rdf:type schema:PropertyValue
95 Nc7724a0b1fae4961bb87ece2f51e4f6b rdf:first sg:person.0645565266.33
96 rdf:rest N85f30690a40e4a67866f8a873957291f
97 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
98 schema:name Medical and Health Sciences
99 rdf:type schema:DefinedTerm
100 anzsrc-for:1107 schema:inDefinedTermSet anzsrc-for:
101 schema:name Immunology
102 rdf:type schema:DefinedTerm
103 sg:grant.2438793 http://pending.schema.org/fundedItem sg:pub.10.1186/s40425-014-0035-z
104 rdf:type schema:MonetaryGrant
105 sg:grant.2622404 http://pending.schema.org/fundedItem sg:pub.10.1186/s40425-014-0035-z
106 rdf:type schema:MonetaryGrant
107 sg:grant.2682501 http://pending.schema.org/fundedItem sg:pub.10.1186/s40425-014-0035-z
108 rdf:type schema:MonetaryGrant
109 sg:journal.1049249 schema:issn 2051-1426
110 schema:name Journal for ImmunoTherapy of Cancer
111 schema:publisher BMJ
112 rdf:type schema:Periodical
113 sg:person.01070606664.05 schema:affiliation grid-institutes:grid.5386.8
114 schema:familyName Kyi
115 schema:givenName Chrisann
116 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01070606664.05
117 rdf:type schema:Person
118 sg:person.0645565266.33 schema:affiliation grid-institutes:grid.5386.8
119 schema:familyName Wolchok
120 schema:givenName Jedd D
121 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0645565266.33
122 rdf:type schema:Person
123 sg:person.0663446543.06 schema:affiliation grid-institutes:grid.5386.8
124 schema:familyName Postow
125 schema:givenName Michael A
126 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0663446543.06
127 rdf:type schema:Person
128 sg:person.0726366600.25 schema:affiliation grid-institutes:grid.5386.8
129 schema:familyName Carvajal
130 schema:givenName Richard D
131 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0726366600.25
132 rdf:type schema:Person
133 grid-institutes:grid.5386.8 schema:alternateName New York-Presbyterian Hospital - Weill Cornell Medical College, 525 E 68th Street, 10065, New York, NY, USA
134 Weill Cornell Medical College, 525 E 68th Street, 10065, New York, NY, USA
135 schema:name Melanoma and Immunotherapeutics Oncology Service, Memorial Sloan Kettering Cancer Center, 300 East 66th Street, 10065, New York, NY, USA
136 New York-Presbyterian Hospital - Weill Cornell Medical College, 525 E 68th Street, 10065, New York, NY, USA
137 Weill Cornell Medical College, 525 E 68th Street, 10065, New York, NY, USA
138 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...